News | November 05, 2006

Barnes-Jewish Hospital Poised for CardioWest Implantation

Washington University surgeons at Barnes-Jewish Hospital, St. Louis, began training at UMC in Tucson on Nov. 2 to become one of only nine hospitals in the U.S. certified to implant the CardioWest temporary Total Artificial Heart (TAH-t). Ranked No. 10 on the “U.S. News and World Report’s” Best Heart Hospitals of 2006, the Barnes-Jewish program has earned a reputation for taking on the most challenging cases, including patients who may have been turned down at other implant centers.

The heart transplant team, led by Dr. Nader Moazami, will be the first in the St. Louis area to be certified to implant the TAH-t, a modern version of the Jarvik-7 Artificial Heart.

The program is known as one of the leading centers in the country for post-transplant care and use of cardiac assist devices.

“We know that it (TAH-t) salvages a large number of patients who are really spiraling downward so rapidly that there’s no other device that can bring them back and this device (the TAH-t) does it,” said Dr. Jack Copeland, who has been a leader in artificial heart surgery since 1985.
The CardioWest TAH-t replaces the patient's dying heart. In most patients it is able to restore cardiac output. This facilitates recovery of vital organs, such as the liver and kidneys that have declined because of low blood flow. This improves the condition of patients who were near death from end stage biventricular heart failure. The TAH-t makes them better able to survive a heart transplant.”


Related Content

News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
News | Pharmaceuticals

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home November 21, 2023
Home
Feature | Pharmaceuticals | By Christine Book

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...

Home October 25, 2023
Home
Videos | Pharmaceuticals

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

Home September 26, 2023
Home
Videos | Pharmaceuticals

In Part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based ...

Home September 11, 2023
Home
Videos | Pharmaceuticals

A 3-part video series with Christine E. Seidman, MD, FACC, FAHA In the first of this 3-part “One on One” series, Dr ...

Home August 28, 2023
Home
News | Pharmaceuticals

August 1, 2023 —LEXEO Therapeutics, a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based ...

Home August 01, 2023
Home
News | Pharmaceuticals

July 10, 2023 — Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio ...

Home July 10, 2023
Home
Subscribe Now